Natco Pharma Limited has announced the receipt of in-principle approval from both the National Stock Exchange of India Limited and BSE Limited on September 21, 2026, for its upcoming rights issue. This approval signifies a crucial step forward in the company’s plan to raise equity capital through the issuance of fully paid-up equity shares. Further details and the official approval letters are accessible via the company’s investor relations website.
Natco Pharma Secures Exchange Approval for Rights Issue
Natco Pharma Limited has officially received in-principle approval from the major stock exchanges, National Stock Exchange of India Limited and BSE Limited, for its proposed rights issue. The approvals were dated September 21, 2026, marking a significant milestone in the company’s capital-raising endeavors.
Details of the Rights Issue
The rights issue will involve the offering of fully paid-up equity shares of the Company. This move is a strategic initiative by Natco Pharma to strengthen its financial position and fund future growth opportunities. The approval from both exchanges indicates the preliminary clearance for the proposed transaction, subject to further regulatory and procedural compliances.
Accessing Approval Documents
For stakeholders seeking detailed information, copies of the in-principal approval letters from the respective stock exchanges have been made available. These documents can be accessed on the official website of Natco Pharma under the investor relations section, specifically within the ‘rights-issue-2026’ subdirectory.
The company expressed its gratitude and confidence in the successful execution of the rights issue.
Source: BSE
